

Silver State Scripts Board Made Changes to the Preferred Drug List Effective April 3, 2025

The Silver State Scripts Board (SSSB) met on March 20, 2025 and voted to adopt the following changes to the Nevada Medicaid Preferred Drug List (PDL) effective April 3, 2025.

The complete PDL is posted on the [“Preferred Drug List”](#) webpage

Drug Class/Program	Changes
Self-Injectable Epinephrine	<ul style="list-style-type: none"> • Drug class name changed from “Self-Injectable Epinephrine” to “Self-Administered Epinephrine” • Neffy® nasal spray added to PDL as non-preferred • Adrenaclick® and Symjepi® removed from PDL due to product discontinuation
Short-Acting Beta Agonists (SABAs)	<ul style="list-style-type: none"> • Airsupra® HFA added to PDL as non-preferred • Levalbuterol concentrated solution moved from preferred to non-preferred • Proair® HFA and Xopenex® removed from PDL due to product discontinuation
Antidepressants: Other	<ul style="list-style-type: none"> • Vilazodone, Spravato®, and Zurzuvae® added to PDL as preferred • Forfivo XL® and Pristiq® moved from preferred to non-preferred
Sulfonylureas	<ul style="list-style-type: none"> • Glimepiride (generic for Amaryl®) 3 mg dose moved from preferred to non-preferred, all other doses (1 mg, 2 mg, and 4 mg) to remain preferred • Amaryl® and Glynase® removed from PDL due to product discontinuation
Immunomodulators: Atopic Dermatitis	<ul style="list-style-type: none"> • Adbry® and pimecrolimus (generic for Elidel®) moved from non-preferred to preferred • Elidel® removed from PDL due to product discontinuation • Ebglyss®, Nemluvio®, and Zoryve® cream added to PDL as non-preferred
Opiate Agonists: Abuse Deterrents	<ul style="list-style-type: none"> • Xtampza® ER removed from PDL due to product no longer participating in Medicaid Drug Rebate Program (MDRP) • Oxycontin® moved from non-preferred to preferred

<p>Miscellaneous Analgesics: Mixed Acting Opioid Analgesics</p>	<ul style="list-style-type: none"> • Nucynta® and Nucynta® ER removed from PDL due to these products no longer participating in the Medicaid Drug Rebate Program (MDRP) • Tramadol IR 25 mg, 75 mg, and 100 mg moved from preferred to non-preferred; 50 mg dose to remain preferred • Tramadol soln moved from preferred to non-preferred • Ultracet® and Seglentsis® removed from PDL due to product discontinuation
<p>Targeted Immunomodulators</p>	<ul style="list-style-type: none"> • Adalimumab-adbm (Qualient manufacturer) to remain non-preferred, while adalimumab-adbm (all other manufacturers) moved to preferred • Adalimumab-adaz moved from non-preferred to preferred • Rinvoq® moved from non-preferred to preferred
<p>Non-Opioid Analgesics</p>	<ul style="list-style-type: none"> • New drug class “Non-Opioid Analgesics” added to the PDL • Includes single agent, Journavx®, which was added as preferred